[go: up one dir, main page]

MX2023008755A - Cristales de sal. - Google Patents

Cristales de sal.

Info

Publication number
MX2023008755A
MX2023008755A MX2023008755A MX2023008755A MX2023008755A MX 2023008755 A MX2023008755 A MX 2023008755A MX 2023008755 A MX2023008755 A MX 2023008755A MX 2023008755 A MX2023008755 A MX 2023008755A MX 2023008755 A MX2023008755 A MX 2023008755A
Authority
MX
Mexico
Prior art keywords
salt crystals
free base
acetylbenzyl
pyrazolo
imidazo
Prior art date
Application number
MX2023008755A
Other languages
English (en)
Inventor
Peng Li
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2023008755A publication Critical patent/MX2023008755A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/20—Sebacic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/10—Polyhydroxy carboxylic acids
    • C07C59/105—Polyhydroxy carboxylic acids having five or more carbon atoms, e.g. aldonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
    • C07C59/153—Glyoxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Seasonings (AREA)

Abstract

La presente descripción se relaciona a una base libre y cristales de sal de 2-(4-acetilbencil)-3-((4 fluorofenil)amino-5,7,7-trimeti l-7,8-dihidro-2H-imidazo[1,2-a]pirazol[4,3-e]pirimidin-4(5H)-ona, composición que comprende la misma y el método para hacer y usar la base libre y cristales de sal.
MX2023008755A 2021-01-27 2022-01-27 Cristales de sal. MX2023008755A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163142073P 2021-01-27 2021-01-27
PCT/US2022/070368 WO2022165494A1 (en) 2021-01-27 2022-01-27 Salt crystals

Publications (1)

Publication Number Publication Date
MX2023008755A true MX2023008755A (es) 2023-08-02

Family

ID=82654920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008755A MX2023008755A (es) 2021-01-27 2022-01-27 Cristales de sal.

Country Status (10)

Country Link
US (1) US20240101569A1 (es)
EP (1) EP4284806A4 (es)
JP (1) JP2024506267A (es)
KR (1) KR20230137364A (es)
CN (1) CN116745303A (es)
AU (1) AU2022214610A1 (es)
CA (1) CA3204146A1 (es)
IL (1) IL304419A (es)
MX (1) MX2023008755A (es)
WO (1) WO2022165494A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021035157A1 (en) * 2019-08-22 2021-02-25 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504931A (ja) * 2007-11-28 2011-02-17 シェーリング コーポレイション プロテインキナーゼ阻害剤としての２−フルオロピラゾロ［１，５−ａ］ピリミジン
GB0811643D0 (en) * 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
EP2717877B1 (en) * 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AU2014234990B2 (en) * 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
US10682354B2 (en) * 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3746081A4 (en) * 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Novel uses
KR20210080418A (ko) * 2018-10-21 2021-06-30 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 용도

Also Published As

Publication number Publication date
IL304419A (en) 2023-09-01
CN116745303A (zh) 2023-09-12
EP4284806A4 (en) 2025-02-26
JP2024506267A (ja) 2024-02-13
KR20230137364A (ko) 2023-10-04
US20240101569A1 (en) 2024-03-28
AU2022214610A1 (en) 2023-07-27
CA3204146A1 (en) 2022-08-04
WO2022165494A1 (en) 2022-08-04
EP4284806A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
IL308438A (en) Pyrido[3,4-D]pyrimidine compounds inhibit mutant KRAS proteins
MX2009004700A (es) Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
MX2021014674A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.
GEP20237581B (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
MX352831B (es) Cristales de sal.
PT1121363E (pt) Pirazole[3,4-d]pirimidin-4-onas substituidas na posicao 6, uteis como inibidores de cinase dependentes de ciclina
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
EA199900855A1 (ru) Соль производного нафтиридинкарбоновой кислоты
CL2021003530A1 (es) Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2009001019A1 (es) Compuestos derivados de pirrolo[1,2-c]imidazol-3-ona, imidazo[indol-3-ona e imidazo[1,5-a]piridin-3-ona sustituidos; procedeimiento de preparacion; su composicion farmaceutica; utiles en el tratamiento de la diabetes, obesidad, trastornos de ingesta d comida o dislepidemia.
MX2023006842A (es) Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
IL276160A (en) A salt of the compound pyrazolo[5,1-]pyrimidine and its crystals
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX2023008755A (es) Cristales de sal.
MX2021002051A (es) Imidazo[1,2-b]piridaziinas como inhibidores de trk.
CA2342830A1 (en) 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
EP4267581A4 (en) SUBSTITUTED IMIDAZO[1,5-B PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND THEIR USE
MX2021000683A (es) Derivados de imidazo[1,2-b]piridazina como inhibidores de trk.
EA200501633A1 (ru) Новые полиморфные формы оланзапина гидрохлорида
UA98797C2 (en) 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro -1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).
EA200500738A1 (ru) КРИСТАЛЛИЧЕСКИЕ ФУМАРАТНЫЕ СОЛИ 1-АЗАБИЦИКЛО [2.2.2]ОКТЗАМЕЩЕННОГО ФУРО [2,3-c] ПИРИДИНИЛКАРБОКСАМИДА И ИХ КОМПОЗИЦИИ И ПОЛУЧЕНИЕ
MX2024008840A (es) Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina.
MX2023005761A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.